Related Experiment Video
Updated: Jun 24, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Many are called MDS cell lines: one is chosen
Hans G Drexler1, Willy G Dirks, Roderick A F Macleod
1DSMZ, German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Lines, Braunschweig, Germany. hdr@dsmz.de
Abstract:
Myelodysplastic syndromes (MDS) comprise a heterogenous group of clonal disorders of hematopoietic progenitors, showing genetic instability and in many cases progression to acute myeloid leukemia (AML). When MDS progress towards AML (AML/MDS), additional genetic lesions cause a block in differentiation and an accumulation of blast cells. Hence, both pathophysiologically and clinically the MDS and AML/MDS phases are distinguishable. Leukemia cell lines are key resources for modelling hematological malignancies. Characterization of these cell lines has provided a rich vein of insights into the mechanisms underlying malignant transformation. Some 31 cell lines have been described in the literature purportedly established from patients with MDS. However, a significant minority of these has proved false after DNA profiling which revealed their cross-contamination with older established leukemia cell lines. Most remaining ("authentic") MDS cell lines were established during the leukemic phase of the disease progression rather than during the MDS phase. Based on these data we have assigned the 31 candidate MDS cell lines to one of the three categories: (1) false (cross-contaminated) cell lines and non-malignant cell lines; (2) malignant cell lines established in the AML/MDS leukemic phase; and (3) apparently legitimate MDS cell lines established during the MDS phase. While MDS and AML/MDS cell lines both provide singular resources for modelling pathology, mining oncogenically modified macromolecules, and testing druggability, we contend these groups should be considered separately.
Insights
This study categorizes 31 cell lines from myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML/MDS) patients. Findings highlight the need to distinguish between MDS and AML/MDS cell lines for accurate research.
Area of Science:
- Hematology
- Cancer Biology
- Cell Line Research
Background:
- Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with genetic instability, often progressing to acute myeloid leukemia (AML).
- Leukemia cell lines are crucial for understanding hematological malignancies, but their authenticity requires rigorous validation.
- Previous characterization revealed cross-contamination in a significant minority of purported MDS cell lines.
Purpose of the Study:
- To critically evaluate and categorize 31 cell lines described as originating from patients with myelodysplastic syndromes (MDS).
- To differentiate between cell lines established during the MDS phase versus the leukemic AML/MDS phase.
- To assess the utility and distinct characteristics of MDS and AML/MDS cell lines in research.
Main Methods:
- DNA profiling to identify cross-contaminated cell lines.
- Literature review and data analysis to categorize cell lines based on their origin (MDS phase, AML/MDS phase, or false).
- Comparative assessment of cell line characteristics and research applications.
Main Results:
- Categorization of 31 candidate MDS cell lines into three groups: false/non-malignant, established in the AML/MDS phase, and established in the MDS phase.
- Identification of cross-contamination in a significant number of previously reported MDS cell lines.
- Demonstration that most "authentic" MDS cell lines were derived from the leukemic phase.
Conclusions:
- MDS and AML/MDS cell lines represent distinct biological entities and should be considered separately in research.
- Authentic MDS cell lines, particularly those from the MDS phase, are rare but valuable resources.
- Accurate cell line characterization is essential for reliable modeling of hematological malignancies and drug development.
